Classic Papillary Thyroid Carcinoma with Tall Cell Features and Tall Cell Variant Have Similar Clinicopathologic Features
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: The tall cell variant of papillary thyroid carcinoma (TCVPTC) is more aggressive than classic papillary thyroid carcinoma (PTC), but the percentage of tall cells needed to diagnose TCVPTC remains controversial. In addition, little is known about the clinicopathologic features of classic PTC with tall cell features (TCF). Methods: We retrospectively selected and reviewed the clinicopathologic features and presence of the BRAF mutation in 203 cases of classic PTC, 149 cases of classic PTC with TCF, and 95 cases of TCVPTCs, which were defined as PTCs having <10%, 10-50%, and ≥50% tall cells, respectively. Results: TCVPTCs and classic PTCs with TCF did not vary significantly in clinicopathologic characteristics such as pathologic (p) T stage, extrathyroidal extension, pN stage, lateral lymph node metastasis, or BRAF mutations; however, these features differed significantly in TCVPTCs and classic PTCs with TCF in comparison to classic PTCs. Similar results were obtained in a subanalysis of patients with microcarcinomas (≤1.0 cm in size). Conclusions: Classic PTCs with TCF showed a similar BRAF mutation rate and clinicopathologic features to TCVPTCs, but more aggressive characteristics than classic PTCs.
Abstract
Background: The tall cell variant of papillary thyroid carcinoma (TCVPTC) is more aggressive than classic papillary thyroid carcinoma (PTC), but the percentage of tall cells needed to diagnose TCVPTC remains controversial. In addition, little is known about the clinicopathologic features of classic PTC with tall cell features (TCF). Methods: We retrospectively selected and reviewed the clinicopathologic features and presence of the BRAF mutation in 203 cases of classic PTC, 149 cases of classic PTC with TCF, and 95 cases of TCVPTCs, which were defined as PTCs having <10%, 10-50%, and ≥50% tall cells, respectively. Results: TCVPTCs and classic PTCs with TCF did not vary significantly in clinicopathologic characteristics such as pathologic (p) T stage, extrathyroidal extension, pN stage, lateral lymph node metastasis, or BRAF mutations; however, these features differed significantly in TCVPTCs and classic PTCs with TCF in comparison to classic PTCs. Similar results were obtained in a subanalysis of patients with microcarcinomas (≤1.0 cm in size). Conclusions: Classic PTCs with TCF showed a similar BRAF mutation rate and clinicopathologic features to TCVPTCs, but more aggressive characteristics than classic PTCs.
참고문헌 (30)
- LiVolsi VA, "Papillary thyroid carcinoma: an update", Mod Pathol, 24(Suppl 2), pp.S1~S9 (2011)
- LiVolsi VA, "Papillary carcinoma tall cell variant (TCV): a review", Endocr Pathol, 21, pp.12~15 (2010)
- Ostrowski ML, "Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid", Am J Surg Pathol, 20, pp.964~974 (1996)
- Michels JJ, "Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma", Hum Pathol, 38, pp.212~219 (2007)
- Ghossein R, "Papillary thyroid carcinoma tall cell variant", Thyroid, 18, pp.1179~1181 (2008)
- Urano M, "Tall cell variant of papillary thyroid carcinoma: its characteristic features demonstrated by fine-needle aspiration cytology and immunohistochemical study", Diagn Cytopathol, 37, pp.732~737 (2009)
- Choi YJ, "Tall cell variant of papillary thyroid carcinoma: sonographic and clinical findings", J Ultrasound Med, 30, pp.853~858 (2011)
- Jung CK, "Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma", Thyroid, 22, pp.791~797 (2012)
- Hawk WA, "The many appearances of papillary carcinoma of the thyroid", Cleve Clin Q, 43, pp.207~215 (1976)
- Morris LG, "Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival", Thyroid, 20, pp.153~158 (2010)
- Terry JH, "Tall cell papillary thyroid cancer: incidence and prognosis", Am J Surg, 168, pp.459~461 (1994)
- Ghossein RA, "Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications", Thyroid, 17, pp.655~661 (2007)
- Lee SH, "Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma", Diagn Cytopathol, 42, pp.11~17 (2014)
- 민혜숙, "Correlation of Immunohistochemical Markers and BRAF Mutation Status with Histological Variants of Papillary Thyroid Carcinoma in the Korean Population", Journal of Korean Medical Science, 28(4), pp.534~541 (2013), 대한의학회
- Beninato T, "Ten percent tall cells confer the aggressive features of the tall cell variant of papillary thyroid carcinoma", Surgery, 154, pp.1331~1336 (2013)
- Johnson TL, "Prognostic implications of the tall cell variant of papillary thyroid carcinoma", Am J Surg Pathol, 12, pp.22~27 (1988)
- Akslen LA, "Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma", Cancer, 88, pp.1902~1908 (2000)
- Regalbuto C, "The tall cell variant of papillary thyroid carcinoma: clinical and pathological features and outcomes", J Endocrinol Invest, 36, pp.249~254 (2013)
- Ganly I, "Prognostic implications of papillary thyroid carcinoma with tall-cell features", Thyroid, 24, pp.662~670 (2014)
- Rivera M, "Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma", Cancer, 113, pp.48~56 (2008)
- Finkelstein A, "Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct", Histopathology, 60, pp.1052~1059 (2012)
- Jung CK, "The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes", Thyroid, 19, pp.905~913 (2009)
- Jalisi S, "Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis", J Thyroid Res, 2010, pp.325602~ (2010)
- Bernstein J, "Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis", Thyroid, 23, pp.1525~1531 (2013)
- American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19, pp.1167~1214 (2009)
- Adeniran AJ, "Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
- Tufano RP, "BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis", Medicine, 91, pp.274~286 (2012)
- Xing M, "BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management", Ann Surg Oncol, 16, pp.801~803 (2009)
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
- Mesa C Jr, "Conditional activation of RET", PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling, 2006, pp.66, 6521~6529